All In Biotech

Drug Trial Radar · NCT06045299

Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia

Last checked: Nov 20, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Sep 27, 2023

Primary completion

Aug 19, 2024

Study completion Jan 27, 2025

Sponsor

Lead sponsor
Corxel PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
LENZ Therapeutics, Inc
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia

Conditions

  • Presbyopia
  • Near Vision
  • Miosis
  • Eye Diseases

Interventions

  • Aceclidine+Brimonidine combination ophthalmic solutionDrug

    Aceclidine+Brimonidine combination ophthalmic solution

  • Aceclidine ophthalmic solutionDrug

    Aceclidine ophthalmic solution

  • Placebo (Vehicle) ophthalmic solutionDrug

    Placebo (Vehicle) ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best-corrected distance visual acuity (BCDVA) at 40 cmTime frame: 3 hours post-treatment in the study eye at Visit 2 (Day 1)

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • The Second Xiangya Hospital of Central South University

    Changsha, China

  • Ineye Hospital of Chengdu University of TCM

    Chengdu, China

  • Dalian N0.3 people's hospital

    Dalian, China

  • Guang Zhou Aier eye Hospital

    Guangzhou, China

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

    Guangzhou, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, China

  • Affiliated Eye Hospital, Shandong University of Traditional Chinese Medicine

    Jinan, China

  • Shanghai Eye Disease Prevention and Treatment Center

    Shanghai, China

  • Tongji Hospital Of Tongji University

    Shanghai, China

  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School Of Medicine

    Shanghai, China

  • Shanxi Eye Hospital

    Taiyuan, China

  • Tianjin Eye Hospital

    Tianjin, China

  • Tianjin Medical University Eye Hospital

    Tianjin, China

  • Wuhan Aier Eye Hospital

    Wuhan, China

  • Xi'An People's Hospital

    Xi'an, China

  • Henan Eye Hospital & Henan Institute

    Zhengzhou, China

  • Eye Hospital, Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.